Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn